公开(公告)号：EP1981854A1

公开(公告)日：2008-10-22

申请号：EP06846594.7

申请日：2006-12-13

申请人： Bristol-Myers Squibb Company

发明人： PINTO, Donald, J.p. ,  SMALLHEER, Joanne, M. ,  CORTE, James R. ,  HU, Zilun ,  CAVALLARO, Cullen L. ,  GILLIGAN, Paul, J. ,  QUAN, Mimi L. ,  SMITH II, Leon, M.

IPC分类号： C07D233/68 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/08 ,  C07D471/18

CPC分类号： C07D403/04 ,  C07D233/68 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

摘要： The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, M and R11 are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

公开(公告)号：EP1981854B1

公开(公告)日：2011-06-01

申请号：EP06846594.7

申请日：2006-12-13

申请人： Bristol-Myers Squibb Company

发明人： PINTO, Donald, J.p. ,  SMALLHEER, Joanne, M. ,  CORTE, James R. ,  HU, Zilun ,  CAVALLARO, Cullen L. ,  GILLIGAN, Paul, J. ,  QUAN, Mimi L. ,  SMITH II, Leon, M.

IPC分类号： C07D233/68 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/08 ,  C07D471/18

CPC分类号： C07D403/04 ,  C07D233/68 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

摘要： The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, M and R11 are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

摘要翻译： 本发明提供式（I）的化合物或其立体异构体，互变异构体，药学上可接受的盐或溶剂化物形式，其中变量A，L1，M和R11如本文所定义。 式（I）化合物是凝血级联和/或接触活化系统的丝氨酸蛋白酶的选择性抑制剂; 例如凝血酶，因子Xa，因子XIa，因子IXa，因子VIIa和/或血浆激肽释放酶。 具体而言，它涉及选择性因子XIa抑制剂的化合物。 本发明还涉及包含这些化合物的药物组合物以及使用该组合物治疗血栓栓塞性和/或炎症性疾病的方法。